The medical-cost beat was never the point. This quarter had to prove that 2025 was fixable. Mostly, it did. What it did not prove is that the growth engine is back.
By FinancialMarkets.com · July 16, 2026
UnitedHealth's second quarter settled one debate and opened another. The company showed it can control medical costs again. Pricing, benefit design, and medical management are all working. But revenue was flat and membership kept falling. So the new question is simple. Can a smaller, better-priced UnitedHealth grow again? Management now says yes. It reaffirmed its long-term growth target of 13% to 16%. The quarter did not prove that target. That gap is the real story.
Medicare did the heavy lifting
The beat came mostly from Medicare. That was the business at the center of the 2025 collapse. Adjusted earnings were $6.38 a share. The Street had looked for about $4.85 to $4.90. Operating earnings rose 55% to $8.0 billion. Revenue was $112.0 billion, roughly flat with last year.
Tim Noel said Medicare cost trends stayed high. But they ran below the roughly 10% the company had priced for 2026. He credited benefit design, care management, and network choices. He also named a milder respiratory season and prior-year reserves. So this was not a sudden drop in patient usage. It was pricing catching up to still-high costs. That is a more durable signal than a usage dip.
The trade-off is deliberate. UnitedHealthcare's operating margin rose to 4.6% from 2.4%. Operating earnings jumped to $3.9 billion from $2.1 billion. Management now expects Medicare margins above 3% this year. It also expects Medicare Advantage to lose about 1.1 million members. Last quarter the guide was a 1.3 million drop. So the attrition outlook improved a little. The company is trading members for margin. The print says that trade is working.
The tone also changed from last quarter. In April, management stressed early momentum and patience. This quarter it sounded more sure. It raised guidance twice this year. It doubled its buyback plan. It also reaffirmed a long-term growth rate it had gone quiet on.
A strong beat, but not a clean one
The medical care ratio was 86.7%. A year ago it was 89.4%. The Street had expected close to 88.6%. So the ratio beat by almost 190 basis points.
One item complicates the read. The quarter held $860 million of favorable prior-period reserves. Management said most of it tied to 2026 claims, not old years. That is a better sign than a stale reserve release. Recent claims coming in light supports the current thesis. Even so, reserve gains are not repeatable earnings.
The gap between reported and adjusted numbers matters too. GAAP earnings were $6.04 a share. Adjusted earnings were $6.38. The difference is intangible costs, divestitures, and loss-contract reserves. Investors should not annualize the 86.7% ratio. Full-year guidance implies 88.1%, plus or minus 25 basis points. That points to a weaker second half. Costs remain high, and commercial trends are getting worse.
The guidance raise was larger than a routine beat. The new range is $19.50 to $20.00 a share. In April the floor was $18.25. In January it was $17.75. Full-year consensus sat near $18.43. So the raise cleared the Street with room to spare. Wayne DeVeydt was still blunt on costs. He said the results do not show trend bending. They show the company pushing down an already high number.
Where costs are still winning
Medicare improved. Commercial moved the other way. Commercial cost trends ran modestly above 11%. Dan Kueter, who runs the commercial unit, named the drivers. He cited the No Surprises Act dispute process, heavier provider coding, and specialty drugs. He said the dispute process alone adds about 50 basis points of trend this year. He put its total cost impact at 100 basis points or more. He said commercial margins can return to 7% or better. But he called that a multi-year job that runs past 2027.
Medicaid is still losing money. Community and State membership fell 380,000. Much of that was a planned Louisiana exit and eligibility checks. Management still expects negative Medicaid margins this year. It sees them near 1% to 1.7% below breakeven. State rate updates of 6% to 7% still trail medical costs. So Medicaid is stabilizing, not recovering.
Optum Health tells a similar story. Its margin improved, but the business got smaller. Revenue fell 5% to $23.5 billion. It served about 700,000 fewer value-based-care patients. Patrick Conway pointed to real operating gains. Care-transition work cut hospitalizations by about 10% in two regions. The company added nearly 200,000 patient-facing hours. Patient experience rose about 5%. Those are concrete wins. But the model is profitable at a smaller scale. It has not yet shown it can grow from here. The other Optum units held up. Optum Insight earnings rose to $1.4 billion on new AI products. Optum Rx earned $1.5 billion, though scripts fell with lost membership.
Why the stock jumped, and what comes next
The reaction was strong. Shares rose about 7% before the open and hit a new high. They later eased to a mid-single-digit gain on the day. The move was less about the beat itself. It was about proof that 2025 was fixable.
Capital returns added to the signal. The company doubled its buyback plan to at least $5 billion for the year. It had bought back $4 billion by mid-July. It raised the dividend to $9.28 a share. It also guided to about $24 billion in operating cash flow.
A lot was already priced in. The stock had climbed roughly 28% this year before the print. It was already trading above the average analyst target near $427. Morgan Stanley named UnitedHealth a top managed-care pick. It lifted its target to $468 and cited AI-driven savings. Bank of America had turned more positive last month, citing better usage trends. The read-across lifted the whole group. Peers look weaker by comparison. Humana cut its 2026 profit outlook sharply on star-rating damage. Elevance swung to a segment loss on high benefit costs. UnitedHealth's 86.7% ratio stands apart.
The rally still shows how far confidence had fallen. Berkshire Hathaway sold its entire stake about two months ago. Revenue is flat. Membership is shrinking. Medicaid loses money. Commercial costs are rising. Optum Health is healing with fewer patients. A regulatory overhang remains, with the Justice Department probing the Optum tie-up.
Here is the reframed calculus. UnitedHealth has rebuilt its margin engine. It has not yet rebuilt its growth engine. Management chose to stake the growth case in public. It reaffirmed the 13% to 16% long-term target and pointed to 2027. That raises the bar it must now clear. The next proof is not another margin beat. It is stable membership, growing value-based care, and real revenue growth. Until then, this is a credible repair, not a finished turnaround.